Why the study?
The prevalence of multivessel CAD in ACS patients underscores the need for optimal revascularization strategies, amid ongoing debate surrounding PCI, CABG, hybrid interventions, or medical-only management.
What are the optimal strategies and timing for managing non-culprit stenosis in patients with acute coronary syndrome and multivessel coronary disease?
What are the optimal strategies and timing for managing non-culprit stenosis in patients with acute coronary syndrome and multivessel coronary disease?
This review highlights that complete revascularization of non-culprit lesions in ACS patients with multivessel CAD is supported by contemporary evidence to optimize short- and long-term outcomes.
Answers are grounded in this paper and cite their sources.
May inform complete revascularization decisions in ACS multivessel CAD; leaves open optimal timing and subgroups for prospective trials.
The prevalence of multivessel coronary artery disease (CAD) in acute coronary syndrome (ACS) patients underscores the need for optimal revascularization strategies. The ongoing debate surrounding percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), hybrid interventions, or medical-only management adds complexity to decision-making, particularly in specific angiographic scenarios. The article critically reviews existing literature, providing evidence-based perspectives on non-culprit lesion revascularization in ACS. Emphasis is placed on nuances such as the selection of revascularization methods, optimal timing for interventions, and the importance of achieving completeness in revascularization. The debate between culprit-only revascularization and complete revascularization is explored in detail, focusing on ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), including patients with cardiogenic shock. Myocardial revascularization guidelines and recent clinical trials support complete revascularization strategies, either during the index primary PCI or within a short timeframe following the culprit lesion PCI (in both STEMI and NSTEMI). The article also addresses the complexities of decision-making in NSTEMI patients with multivessel CAD, advocating for immediate multivessel PCI unless complex coronary lesions require a staged revascularization approach. Finally, the article provided contemporary data on chronic total occlusion revascularization in ACS patients, highlighting the prognostic impact. In conclusion, the article addresses the evolving challenges of managing multivessel CAD in ACS patients, enhancing thoughtful integration into the clinical practice of recent data. We provided evidence-based, individualized approaches to optimize short- and long-term outcomes. The ongoing refinement of clinical and interventional strategies for non-culprit lesion management remains dynamic, necessitating careful consideration of patient characteristics, coronary stenosis complexity, and clinical context.
No takes yet. Share an insight, caveat, or question.
Manuca et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: